personalized liposomal neoantigen-based peptide vaccine EVX-01

A personalized liposomal peptide vaccine composed of specific cancer neoepitopes, which are highly patient-specific immunogenic tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration of the personalized liposomal neoantigen-based peptide vaccine EVX-01, the neoepitopes induce cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells expressing these specific TAAs.